Genmab A-S

Yahoo Finance • 5 days ago

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Electronic Arts Inc. (Nasdaq - EA), Merus N.V. (Nasdaq – MRUS), Berry Corporation (Nasdaq - BRY), Semler Scientific, Inc. (Nasdaq – SMLR)

BALA CYNWYD, Pa., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ack... Full story

Yahoo Finance • 7 days ago

Notable healthcare headlines for the week: Pfizer, Novo Nordisk and JNJ in focus

Wall Street’s broader market averages closed mixed on Friday as market participants digested the U.S. government shutdown for the third day. For the week, the Dow, S&P 500, and Nasdaq Composite advanced by 1.1%, 1.08%, and 1.32%, respecti... Full story

Yahoo Finance • 12 days ago

EQT Life Sciences portfolio company Merus to be acquired by Genmab in an all-cash USD 8.0 billion transaction

Genmab has entered into a definitive agreement to acquire Merus in an all-cash transaction for a total consideration of USD 8.0 billion, making it one of the largest acquisitions of a European biotech company to date Merus is a clinical-st... Full story

Yahoo Finance • 13 days ago

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Electronic Arts Inc. (Nasdaq – EA), Merus N.V. (Nasdaq – MRUS), Berry Corporation (Nasdaq – BRY), Semler Scientific, Inc. (Nasdaq – SMLR)

BALA CYNWYD, Pa., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ac... Full story

Yahoo Finance • 13 days ago

Genmab Strikes $8 Billion Deal To Acquire Cancer-Focused Merus

Genmab, on Monday, announced its plan to buy Merus for about $8 billion. The news sent Merus stock into the stratosphere. Continue Reading View Comments... Full story

Yahoo Finance • 13 days ago

Genmab Makes $8 Billion Bet On Merus With Potential Cancer Breakthrough

Genmab A/S (NASDAQ: GMAB) on Monday agreed to acquire Merus N.V. (NASDAQ: MRUS) with its late-stage asset petosemtamab, which is in Phase 3 development, for $97 per share in an all-cash transaction representing a transaction value of appro... Full story

Yahoo Finance • 13 days ago

Trending tickers: Alibaba, AstraZeneca, GSK, Stellantis and Genmab

Alibaba (9988.HK, BABA) Hong Kong-listed shares in Alibaba (9988.HK) rose more than 4% on Monday, while its New York-listed American Depository Shares (ADRs) (BABA) were up by nearly 4% in pre-market trading, after analysts raised their p... Full story

Yahoo Finance • 13 days ago

Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model

Company Announcement Genmab to acquire Merus for USD 97.00 per share in an all-cash transaction representing a transaction value of approximately USD 8.0 billionProposed acquisition adds petosemtamab, a late-stage asset with two Breakthro... Full story

Yahoo Finance • 14 days ago

Genmab reportedly nearing deal to acquire cancer drug developer Merus

[M&A - concept waiting for mergers and acquisitions.3D rendering on yellow background.] Danish biotech Genmab (GMAB [https://seekingalpha.com/symbol/GMAB]) is in advanced discussions to acquire Merus (NASDAQ:MRUS [https://seekingalpha.com... Full story

Yahoo Finance • 17 days ago

Grant of Restricted Stock Units and Warrants to Employees in Genmab

Company Announcement COPENHAGEN, Denmark; September 26, 2025 – Genmab A/S (Nasdaq: GMAB) announced today that the Board of Directors decided to grant 14,353 restricted stock units and 9,681 warrants to employees of the Company and the Com... Full story

Yahoo Finance • 19 days ago

Genmab upgraded at Guggenheim; says Darzalex related growth concerns are overblown

[Business on Wall Street in Manhattan] Pgiam/iStock via Getty Images Guggenheim upgraded Genmab (GMAB [https://seekingalpha.com/symbol/GMAB]) to Buy from Neutral on Tuesday, arguing that concerns over the Danish biotech’s growth prospects... Full story

Yahoo Finance • 19 days ago

Major Shareholder Announcement

Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; September 23, 2025 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital Markets Act that Orbis Investment Manage... Full story

Yahoo Finance • 25 days ago

Bernstein Reiterates a Sell Rating on Genmab A/S (GMAB)

Genmab A/S (NASDAQ:GMAB) is one of the best affordable biotech stocks to invest in now. In a report released on September 8, Justin Smith from Bernstein reiterated a Sell rating on Genmab A/S (NASDAQ:GMAB) without assigning a price target.... Full story

Yahoo Finance • last month

Genmab A/S (GMAB) Scores FDA Breakthrough for Rina-S

In this article, we will be taking a look at the 11 Best Performing Biotech Stocks So Far in 2025. Genmab A/S stands fifth among them. Genmab A/S (NASDAQ:GMAB) is strengthening its position as a global leader in antibody-based therapies w... Full story

Yahoo Finance • last month

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Company Announcement COPENHAGEN, Denmark; September 9, 2025 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of t... Full story

Yahoo Finance • last month

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Company Announcement COPENHAGEN, Denmark; September 09, 2025 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 47,532 shares as a consequence of the exercise of employee warrants. The increase is effected without any preempt... Full story

Yahoo Finance • last month

GENMAB A/S -SP ADR (NASDAQ:GMAB) Meets Peter Lynch's GARP Investment Criteria

In the world of long-term investing, few strategies have shown as much lasting appeal as the method made popular by Peter Lynch. His approach, described in _One Up on Wall Street_, focuses on finding companies with lasting growth paths, fa... Full story

Yahoo Finance • last month

GENMAB A/S -SP ADR (NASDAQ:GMAB): A High-Value Biotech Play with Strong Fundamentals

In the search for undervalued opportunities, value investors often use screening strategies that find companies trading below their intrinsic worth while keeping solid fundamental health. One such approach is the "Decent Value" screen, whi... Full story

Yahoo Finance • last month

Genmab A/S (GMAB)’s Epcoritamab Delivers 95% Response in Lymphoma

We recently published 11 Best Cancer Stocks to Buy Right Now. Genmab A/S is placed ninth among the best cancer stocks. Genmab A/S (NASDAQ:GMAB), a Danish biotechnology leader, specializes in antibody-based therapies for cancer and serious... Full story

Yahoo Finance • last month

Genmab A/S (GMAB) Expands Tivdak and Epkinly Commercial Push Globally

We recently compiled a list of the 11 Cheap Biotech Stocks to Buy According to Hedge Funds.Genmab A/S is one of them. Genmab A/S (NASDAQ:GMAB), based in Copenhagen, is a biotechnology company focused on developing antibody-based therapies... Full story